Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
|Podcasts|May 26, 2021
Neoadjuvant and Adjuvant Treatment of HER2-Positive Breast Cancer
Author(s)OncLive Staff
Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.
Advertisement
Advertisement
Related to this article
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
The European Commission approved T-DXd for patients with HER2+ breast cancer who have residual invasive disease after neoadjuvant treatment.
A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026
5